- Home
- VNO vs LNTH Comparison
VNO vs LNTH Comparison
Compare VNO & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- LNTH
- Stock Information
- Founded
- VNO 1946
- LNTH 1956
- Country
- VNO United States
- LNTH United States
- Employees
- VNO N/A
- LNTH N/A
- Industry
- VNO Real Estate Investment Trusts
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VNO Real Estate
- LNTH Health Care
- Exchange
- VNO Nasdaq
- LNTH Nasdaq
- Market Cap
- VNO 7.0B
- LNTH 7.5B
- IPO Year
- VNO N/A
- LNTH 2015
- Fundamental
- Price
- VNO $40.19
- LNTH $79.52
- Analyst Decision
- VNO Hold
- LNTH Strong Buy
- Analyst Count
- VNO 11
- LNTH 5
- Target Price
- VNO $38.00
- LNTH $133.80
- AVG Volume (30 Days)
- VNO 1.3M
- LNTH 1.2M
- Earning Date
- VNO 05-05-2025
- LNTH 05-07-2025
- Dividend Yield
- VNO 1.84%
- LNTH N/A
- EPS Growth
- VNO 248.25
- LNTH N/A
- EPS
- VNO 0.52
- LNTH 3.53
- Revenue
- VNO $1,929,890,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- VNO N/A
- LNTH $5.81
- Revenue Next Year
- VNO $5.02
- LNTH $12.26
- P/E Ratio
- VNO $74.16
- LNTH $22.52
- Revenue Growth
- VNO 2.98
- LNTH 12.53
- 52 Week Low
- VNO $22.42
- LNTH $74.34
- 52 Week High
- VNO $46.63
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- VNO 66.19
- LNTH 28.34
- Support Level
- VNO $38.45
- LNTH $78.92
- Resistance Level
- VNO $39.73
- LNTH $108.91
- Average True Range (ATR)
- VNO 1.25
- LNTH 3.92
- MACD
- VNO 0.61
- LNTH -3.09
- Stochastic Oscillator
- VNO 92.40
- LNTH 3.00
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.